Arcutis Biotherapeutics (ARQT) rallied 30.9% in the past month after the FDA approved the supplemental new drug application (sNDA) for its marketed product, Zoryve (roflumilast) cream 0.15%, to treat mild to moderate atopic dermatitis (AD) in adult and pediatric patients aged six years and older.AD, also known as eczema, is a chronic skin disease characterized by itchy and inflamed skin, primarily common in children. Per Arcutis, 9.6 million children and 16.5 million adults in the United States are affected ...